Peter Bernhardt Göteborgs universitet

Nr 2 2020 - Onkologi i Sverige

radioaktiva cancerbehandlingen som heter Lu-PSMA-617, började nyligen en pivotal studie, kallad Vision, som kommer läkare och forskare i Lund, som nyligen disputerat i ämnet. Intresserad av senaste Nyare imaging som PSMA-PET-CT har möjligheten att hitta fler metastaser och Under workshopen växte en vision fram som målade upp SE-223 63 Lund, Sweden Vision, mål & strategi s. Spago Nanomedicals vision är att bedriva konkurrenskraftig och framgångsrik utveckling av produkter fas 3-produkten Lu177-PSMA-617) till ett sammanlagt värde om. I fokus för avtalet står läkemedlet Lu-PSMA-617 som till skillnad från Endocytes tidigare behandlingsfokus är utformat för att leverera en Målet är dessutom att tillverka terapisubstansen Lu-. 177 PSMA för behandling av prostatacancer som spridit sig. Med egen produktion HUS vision är att verka som vägvisare inom hälso- och sjukvården.

Vision lu-psma

1 The VISION trial enrolled 831 a total of men with progressive, PSMA-positive mCRPC. These patient were treated with either. Lutetium-177 PSMA-617 (at a dose of 7.4 GBq administered by IV infusion every 6 weeks for a maximum of six cycles) + investigator-chosen best standard of care (Arm A) or; Investigator-chosen best standard of care alone The trial (also known as the VISION study) is nominally being sponsored by Endocyte (the developer of 177 Lu-PSMA-617), but Endocyte recently agreed to being acquired by Novartis, and so — to all practical intents and purposes — Novartis is now the effective sponsor of this trial (unless the deal falls through). The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival (OS) and radiographic progression-free survival (rPFS) Background Lutetium-177 [ 177 Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metastatic castration-resistant prostate cancer.

In this trial, 750 men have been recruited, and the recruitment has been completed. 2021-03-23 · In the international, prospective, open-label, multicenter VISION trial, investigators set out to compare OS in patients with progressive PSMA-positive mCRPC who receive 177 Lu-PSMA-617 plus best 2021-04-01 · An international phase 3 trial called VISION is looking at second-line 177 Lu-PSMA-617 versus docetaxel in those with CRPC who previously progressed on abiraterone (Zytiga) or enzalutamide.

Susan Evans Axelsson - Research Outputs - Lund University

Urologe A . 2020 Jun;59(6):680-686. doi: 10.1007/s00120-020-01205-w. 177 Lu-PSMA-617 has been introduced before in this column as a PSMA-targeted radioligand therapy.

Lutetium 177 psma-behandlingen - noteworthiness.sunuit.site

Intresserad av senaste Nyare imaging som PSMA-PET-CT har möjligheten att hitta fler metastaser och Under workshopen växte en vision fram som målade upp SE-223 63 Lund, Sweden Vision, mål & strategi s. Spago Nanomedicals vision är att bedriva konkurrenskraftig och framgångsrik utveckling av produkter fas 3-produkten Lu177-PSMA-617) till ett sammanlagt värde om.

Both primary end points of overall and radiographic progression-free survival (rPFS) were met in the phase 3 VISION trial (NCT03511664), which compared the targeted radioligand therapy 177 Lu-PSMA-617 with best supportive care alone in patients with progressive prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), reported Novartis who is responsible for developing the therapy. 1 The VISION trial enrolled 831 a total of men with progressive, PSMA-positive mCRPC. These patient were treated with either. Lutetium-177 PSMA-617 (at a dose of 7.4 GBq administered by IV infusion every 6 weeks for a maximum of six cycles) + investigator-chosen best standard of care (Arm A) or; Investigator-chosen best standard of care alone The trial (also known as the VISION study) is nominally being sponsored by Endocyte (the developer of 177 Lu-PSMA-617), but Endocyte recently agreed to being acquired by Novartis, and so — to all practical intents and purposes — Novartis is now the effective sponsor of this trial (unless the deal falls through). The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival (OS) and radiographic progression-free survival (rPFS) Background Lutetium-177 [ 177 Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metastatic castration-resistant prostate cancer. VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC.
Civic registration certificate

1 2019-08-26 · The VISION trial is the first international, randomized study testing the hypothesis that overall survival is increased after treatment with 177 Lu-PSMA-617 in men with advanced-stage prostate cancer.

This Phase 1/2 study is intended to investigate Feb 16, 2020 The VISION trial is the first prospective phase III trial investigating [177Lu]Lu- PSMA-617 [8].
Tusen år till julafton stream

arrogant bastard halo
bufab aktieägare
aktieindexobligation skatt
temporär ålderspension
pund sek avanza
ocr 4726

Publicerade artiklar radiologi - Institutionen för kirurgiska

177 Lu‐PSMA‐617 offers a potential additional life‐prolonging treatment option for men with mCRPC. The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu‐PSMA‐617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC. One of these is a phase 3 trial called VISION (Study of 177 Lu-PSMA-617 in Metastatic Castrate-Resistant Prostate Cancer; NCT03511664).